The Cell--Extrinsic role of CHD1 in Prostate Cancer Development and Progression

Di Zhao1,2, Xin Lu1, Li Cai1, Guocan Wang4, Xin Liang4, Peiwen Chen1, Zhengdao Lan1, Jun Li2, Xiaoying Shang1, Ming Tang2, Jiexi Li2, Pingna Deng1, Wenting Liao1, Denise J. Spring1, Sumit K Subudhi4, Jian H. Song4, Christopher J. Logothetis4, Y. Alan Wang1, and Ronald A. DePinho*, 1

1Department of Cancer Biology
2Department of Experimental Radiation Oncology
3Institute for Applied Cancer Science
4Department of Genitourinary Medical Oncology
5Department of Genomic Medicine
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Background: Prostate cancer (PCa) invariably becomes refractory to androgen deprivation therapy (ADT), resulting in the development of metastatic castration resistant prostate cancer (mCRPC) with high morbidity and mortality. A majority of localized and metastatic prostate cancer shows loss of PTEN; therefore, identification of specific therapeutic targets and effective combinations for PCa harboring deficiencies of PTEN holds hope for patients with advanced PCa. mCRPC shows overwhelming de novo resistance to immune checkpoint blockade, motivating the study of tumor microenvironment to overcome this resistance. Taking advantage of the vast public available prostate cancer genome database, I identified the chromatin remodeling protein CHD1 as a synthetic essential gene in PTEN-deficient PCa through regulating NF-KB pathway genes.

Method: To investigate CHD1 function on prostate cancer progression, I generated PB-Cre, PtenL/L, Chd1L/L and PB-Cre, PtenL/L, Smad4L/L, Chd1L/L genetically engineered mouse (GEM) models, and performed histopathology analysis, transcriptomic profiling and immunophenotype profiling.

Results: So far, delayed tumor development, decreased lymph node metastasis has been observed in Chd1 depleted prostate tissues. Importantly, a significantly prolonged overall survival has been observed in CHD1 depletion mice, compared to mice with Pten loss PCa. To further uncover the mechanism underlying the CHD1 depletion phenotype, unbiased transcriptomic profiling was performed. In addition to several well-known oncogenic signaling pathways, such as EMT and Myc pathways, I also identified down-regulated inflammatory pathways upon CHD1 inhibition, prompting me to determine whether CHD1 affects TME remodeling in Pten-deficient PCa. Mass Cytometry (CyTOF) was also performed in PtenChd1 DKO mice to identify the immunophenotype. The data suggested that CHD1 directly regulates myeloid-derived suppressor cell (MDSCs) infiltration in prostate cancer, which play key roles in immune suppression. Meanwhile, CHD1 depletion boosted tumor-infiltrating CD8+ T-cells, rather than CD4+ T-cell, NK cells or B cells. Mechanistically, I uncovered that CHD1 directly regulates cytokine IL6 gene expression and thereby recruits MDSCs into PCa tumor, which suppresses CD8+ T cell proliferation and activity. In addition, I also evaluated the anti-tumor effects of inhibition CHD1/IL6 pathway alone or in combination with immune checkpoint blockade (ICB) in Pten deficient prostate cancer mouse model.

Conclusions: These data suggested that CHD1 plays essential roles on PTEN-deficient PCa, and CHD1 contributes to MDACs mediated immunosuppressive TME in PTEN-deficient PCa. Targeting the CHD1/IL6 axis alone or in combination with ICB provide novel therapeutic strategies for PCa patients with PTEN loss.

Conflict of Interest: None

Funding Acknowledgements: PCF Young Investigator Award; NCI K99/R00 Award; CPRIT Award